WEP CLINICAL HAS PARTNERED WITH KYOWA KIRIN TO LAUNCH POTELIGEO® (mogamulizumab) POST-APPROVAL NAMED PATIENT PROGRAM IN ASIA PACIFIC
WEP Clinical LTD (WEP), a specialist services company that [...]
WEP CLINICAL HAS PARTNERED WITH PHARMING GROUP TO SUPPLY LENIOLISIB POST-FDA APPROVAL THROUGH A POST-APPROVAL NAMED PATIENT PROGRAM
WEP Clinical LTD (WEP), a specialist services company that [...]
Who is in Charge of Granting Pre-Approval Drug Access?
Patients suffering from rare diseases or life-threatening illnesses, like cancer, [...]
What Patients are Eligible for Pre-Approval Drug Access?
Recently approved legislation, the “Trickett Wendler, Frank Mongiello, Jordan McLinn, [...]
Why Collect Real World Data (RWD)
Randomized controlled trials (RCTs) have long served as the gold [...]
WEP CLINICAL PARTNERS WITH SOLASIA PHARMA K.K. TO LAUNCH DARVIAS NAMED PATIENT PROGRAM
WEP Clinical LTD (WEP), a specialist services company that [...]
WEP CLINICAL PARTNERS WITH Y-MABS THERAPEUTICS TO PROVIDE DANYELZA THROUGH A NAMED PATIENT ACCESS PROGRAM IN EUROPE
WEP Clinical (WEP) is pleased to announce a new [...]
WEP CLINICAL HAS PARTNERED WITH TAIMED BIOLOGICS TO LAUNCH A TROGARZO NAMED PATIENT PROGRAM
WEP Clinical LTD (WEP), a specialist services company that [...]
Three Things Patients Should Know About Companies Providing Expanded Access Use of their Investigational Drugs
Expanded Access Programs (EAPs), also referred to as Managed Access [...]
Key Expanded Access Strategies All Companies Should Adopt
Recent conversation regarding expanded access has focused heavily on the [...]